• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Chemours (CC) Appointing Michael Foley To Lead Titanium Technologies

    Simply Wall St·12/05/2025 23:28:57
    Listen to the news
    • The Chemours Company recently announced that Michael Foley will become President of Chemours Titanium Technologies in February 2026, bringing experience leading a US$1.00 billion specialty chemicals portfolio at Momentive Performance Materials.
    • Foley’s background in portfolio optimization, organizational restructuring, and Lean and Six Sigma practices signals a potential shift in how Chemours manages efficiency and profitability in its core titanium dioxide segment.
    • Now we’ll examine how Foley’s appointment to lead Titanium Technologies may influence Chemours’ existing investment narrative and risk-reward profile.

    AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Chemours Investment Narrative Recap

    To own Chemours today, you need to believe that its core titanium dioxide and fluorochemicals businesses can convert operational improvements into durable cash generation despite ongoing losses and PFAS overhangs. Foley’s appointment to lead Titanium Technologies is a longer-dated development and does not materially change the near term focus on stabilizing earnings and managing litigation and regulatory risk.

    Recent analyst actions, including JP Morgan’s Neutral rating and reduced US$13.00 price target, frame Foley’s hire against a backdrop of tempered expectations and a Hold-leaning consensus. That context matters as investors weigh potential efficiency gains in Titanium Technologies against persistent concerns around legal liabilities, regulatory costs, and cyclical TiO₂ demand.

    Yet while leadership change may support long term execution, investors should be aware of how unresolved PFAS litigation could still...

    Read the full narrative on Chemours (it's free!)

    Chemours' narrative projects $6.6 billion revenue and $671.0 million earnings by 2028.

    Uncover how Chemours' forecasts yield a $17.78 fair value, a 40% upside to its current price.

    Exploring Other Perspectives

    CC Community Fair Values as at Dec 2025
    CC Community Fair Values as at Dec 2025

    Five fair value estimates from the Simply Wall St Community span roughly US$11.55 to US$26.59, underlining how far apart individual views can be. You may want to compare those opinions with the risk that unresolved PFAS and environmental liabilities could pressure Chemours’ cash flows and influence how the market values any operational progress in Titanium Technologies.

    Explore 5 other fair value estimates on Chemours - why the stock might be worth 9% less than the current price!

    Build Your Own Chemours Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Looking For Alternative Opportunities?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.